BRIEF-Abeona Receives FDA Orphan Drug Status For Gene Therapy To Treat Rare Disease In Newborns
February 12, 2018 at 08:49 AM EST
* ABEONA THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ABO-202 GENE THERAPY PROGRAM IN INFANTILE BATTEN DISEASE
